Physician profile
Saeed Uddin Khan
NPI 1790834273
$7,970.75
in general payments reported to CMS, 2019-2025
36 companies · $975 in 2025
The $975 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $1,011 · 2021: $687 · 2022: $1,155 · 2023: $1,557 · 2024: $1,688 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,861 · Education: $334 · Consulting Fee: $24.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.78 |
| Education | $334.06 |
| Consulting Fee | $24.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,882.69 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $1,296.49 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Harmony Biosciences LLC | $549.44 | 2020-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.48 | 2019-2024 | Ofev |
| Abbvie INC. | $401.62 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $394.92 | 2019-2024 | Dupixent |
| Genzyme Corporation | $347.72 | 2019-2024 | |
| Philips North America LLC | $272.44 | 2019-2024 | (Ak6) Vest Therapy |
| Electromed, INC. | $232.95 | 2019-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $189.98 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $171.16 | 2019-2021 | |
| Genentech USA, INC. | $158.44 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $155.30 | 2019-2024 | Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $149.68 | 2020-2023 | Glassia |
| Amgen INC. | $149.54 | 2024-2025 | Tezspire |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $140.44 | 2020-2024 | |
| Portola Pharmaceuticals, LLC | $131.72 | 2019 | |
| Merck Sharp & Dohme LLC | $123.82 | 2019-2024 | Recarbrio, Zerbaxa |
| Baxter Healthcare | $91.24 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Pulmonx Corporation | $90.63 | 2023-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Grifols USA, LLC | $86.12 | 2019-2023 | Prolastin-C Liquid |
| Pfizer INC. | $67.28 | 2021-2025 | |
| United Therapeutics Corporation | $52.86 | 2019-2020 | |
| Insmed, INC. | $48.99 | 2022-2024 | Arikayce |
| Shionogi INC | $46.43 | 2022-2023 | Fetroja |
| Teva Pharmaceuticals USA, INC. | $40.32 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $25.50 | 2019 | |
| Adma Biomanufacturing LLC | $24.71 | 2025 | |
| Csl Behring | $24.11 | 2020 | |
| Gilead Sciences, INC. | $23.42 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.77 | 2021 | |
| Circassia INC. | $16.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.25 | 2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $15.59 | 2019 | |
| Vapotherm INC | $14.33 | 2022 | |
| Veran Medical Technologies, INC. | $13.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saeed Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.